Vanda Pharmaceuticals (VNDA) Stock Price, Quote & News

Company Profile

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for prev...

Industry: Biotechnology

Sector: Healthcare

Phone: 202 734 3400

Website: www.vandapharma.com

Address:

2200 Pennsylvania Avenue NW, Suite 300E, Washington, United States

Rawbinhood Apr. 14 at 5:10 PM

$VNDA New Filings of Form 3s

0 · Reply

chuckL4 Apr. 14 at 4:36 PM

$VNDA With biotech so strong it is hard to understand why VNDA is such a laggard given its products, pipeline and valuation. Given their cash position, could management be using their shelf to raise even more cash at these low levels. Seems like they should be cutting expenses and buying back stock.

0 · Reply

CaptE518 Apr. 14 at 2:41 PM

$VNDA This just needs volume and they will not be able to control it anymore. Lets Go!!

0 · Reply

aniroth Apr. 14 at 2:29 PM

$VNDA biotech low attention could move if volume spikes

0 · Reply

Nebler Apr. 14 at 2:27 PM

$VNDA every spike is getting killed immediately

0 · Reply

sck2 Apr. 14 at 1:38 PM

$VNDA

0 · Reply

sck2 Apr. 14 at 11:22 AM

$VNDA 🕵️‍♂️🔑

0 · Reply

CaptE518 Apr. 14 at 11:08 AM

$VNDA Another super green day today in the market!! My guess is that they will pin it at 7.22!!! We see you!!!

0 · Reply

sck2 Apr. 14 at 11:00 AM

$VNDA . https://www.facebook.com/reel/908200118587971

1 · Reply

sck2 Apr. 13 at 10:21 PM

$VNDA for how long are they going to hold her at this level? wt 💪💥🚀

1 · Reply

Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines

Apr 8, 2026, 4:44 PM EDT - 5 days ago

Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists

Mar 19, 2026, 4:34 PM EDT - 25 days ago

Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods

Mar 3, 2026, 8:01 AM EST - 6 weeks ago

Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years

Feb 26, 2026, 4:35 PM EST - 6 weeks ago

Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference

Feb 25, 2026, 10:56 AM EST - 6 weeks ago

Vanda Pharmaceuticals Breaks Through With FDA Approval, Decision Date For Skin Drug

Feb 25, 2026, 7:18 AM EST - 6 weeks ago

Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

ANAB

Feb 23, 2026, 10:28 AM EST - 7 weeks ago

Vanda Pharmaceuticals stock's explosive rally may be more hype than substance

Feb 23, 2026, 9:00 AM EST - 7 weeks ago

Vanda Pharmaceuticals FDA Approval Dawns A New Era For Bipolar And Schizophrenia Treatment

Feb 20, 2026, 6:03 PM EST - 7 weeks ago

US FDA approves Vanda's psychiatric drug

Feb 20, 2026, 5:59 PM EST - 7 weeks ago

Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation

Feb 11, 2026, 4:01 PM EST - 2 months ago

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 4, 2026, 6:01 PM EST - 2 months ago

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

Jan 8, 2026, 9:31 AM EST - 3 months ago

Vanda and Exante Data Combine in Strategic Merger

Jan 8, 2026, 7:00 AM EST - 3 months ago

Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder

Dec 31, 2025, 10:57 AM EST - 3 months ago

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval

Dec 30, 2025, 6:30 PM EST - 3 months ago

US FDA approves Vanda Pharmaceuticals' motion sickness drug

Dec 30, 2025, 6:13 PM EST - 3 months ago

Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness

Dec 15, 2025, 7:00 AM EST - 4 months ago

Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

ANAB

Dec 11, 2025, 5:02 PM EST - 4 months ago

Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference

Dec 4, 2025, 4:21 PM EST - 4 months ago

FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness

Nov 28, 2025, 7:00 AM EST - 4 months ago

Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness

Nov 18, 2025, 10:49 AM EST - 5 months ago

Side Effects From Wegovy? This Vanda Pharmaceuticals' Drug Halves Vomiting In Patients

Nov 17, 2025, 6:37 PM EST - 5 months ago

Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting

Nov 5, 2025, 5:00 PM EST - 5 months ago

Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference

Oct 29, 2025, 4:01 PM EDT - 5 months ago

Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results

Oct 22, 2025, 4:30 PM EDT - 6 months ago

Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025

Oct 8, 2025, 8:00 AM EDT - 6 months ago

Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena

Oct 1, 2025, 5:02 PM EDT - 6 months ago

Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration

Sep 25, 2025, 8:00 AM EDT - 7 months ago

Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial"

Aug 28, 2025, 5:23 PM EDT - 8 months ago

Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences

Aug 28, 2025, 7:00 AM EDT - 8 months ago

Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera

Aug 21, 2025, 4:40 PM EDT - 8 months ago

Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®

Aug 18, 2025, 7:00 AM EDT - 8 months ago

In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder

Jul 31, 2025, 7:30 AM EDT - 9 months ago

Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results

Jul 23, 2025, 4:45 PM EDT - 9 months ago

Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025

Jun 10, 2025, 8:00 AM EDT - 11 months ago

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S

May 27, 2025, 9:00 AM EDT - 11 months ago

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting

May 16, 2025, 5:30 PM EDT - 11 months ago

Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025

May 7, 2025, 4:01 PM EDT - 1 year ago

Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

May 5, 2025, 8:00 AM EDT - 1 year ago

Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026

May 2, 2025, 8:46 AM EDT - 1 year ago

Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025

Apr 23, 2025, 3:52 PM EDT - 1 year ago

FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA

Apr 7, 2025, 8:00 AM EDT - 1 year ago

Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia

Feb 24, 2025, 7:00 AM EST - 1 year ago

Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"

Feb 13, 2025, 4:01 PM EST - 1 year ago

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Rawbinhood Apr. 14 at 5:10 PM

$VNDA New Filings of Form 3s

0 · Reply

chuckL4 Apr. 14 at 4:36 PM

0 · Reply

CaptE518 Apr. 14 at 2:41 PM

$VNDA This just needs volume and they will not be able to control it anymore. Lets Go!!

0 · Reply

aniroth Apr. 14 at 2:29 PM

$VNDA biotech low attention could move if volume spikes

0 · Reply

Nebler Apr. 14 at 2:27 PM

$VNDA every spike is getting killed immediately

0 · Reply

sck2 Apr. 14 at 1:38 PM

$VNDA

0 · Reply

sck2 Apr. 14 at 11:22 AM

$VNDA 🕵️‍♂️🔑

0 · Reply

CaptE518 Apr. 14 at 11:08 AM

$VNDA Another super green day today in the market!! My guess is that they will pin it at 7.22!!! We see you!!!

0 · Reply

sck2 Apr. 14 at 11:00 AM

$VNDA . https://www.facebook.com/reel/908200118587971

1 · Reply

sck2 Apr. 13 at 10:21 PM

$VNDA for how long are they going to hold her at this level? wt 💪💥🚀

1 · Reply

CaptE518 Apr. 13 at 9:38 PM

$VNDA On a Super Green day, we still go down in price. Cant make this shit up. Let it fucking rip already!!

0 · Reply

Smaith Apr. 13 at 8:12 PM

$VNDA 372k buy at close

0 · Reply

TomMac64 Apr. 13 at 7:56 PM

$VNDA Still looks good to me …. I’ve got plenty of patience for this gem !

0 · Reply

jags2255 Apr. 13 at 7:34 PM

$VNDA Piece of shit mms just won’t let it go

0 · Reply

sck2 Apr. 13 at 6:36 PM

$VNDA 🕵️💪💎

0 · Reply

chuckL4 Apr. 13 at 2:07 PM

$VNDA With takeovers in biotech and the XBI up over 2%, hard to believe VNDA is slightly down. Would think this ultra cheap stock is high on the takeover list, especially LLY and NVO

1 · Reply

sck2 Apr. 13 at 2:01 PM

$VNDA ✅💪💥🚀

0 · Reply

BullMaven Apr. 13 at 1:30 PM

$VNDA keep loading. Will be 10+ soon

0 · Reply

BioRich Apr. 13 at 2:39 AM

$XBI $MIST $OGN $VNDA $GUTS lead my list of Bios to watch this week. Which ones are you going to be following closely or think will have a pop this week? Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

2 · Reply

sck2 Apr. 12 at 6:14 PM

$VNDA

0 · Reply

sck2 Apr. 12 at 6:04 PM

$VNDA 🕵️‍♂️

0 · Reply

yoyohmm Apr. 12 at 4:56 PM

$VNDA BO 🥳

0 · Reply

Market Cap	426.76M
Revenue (ttm)	216.11M
Net Income (ttm)	-220.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-102.02%
Debt to Equity Ratio	0.00

Volume	743,792
Avg Vol	2,858,608
Day's Range	N/A - N/A
Shares Out	59.11M
Stochastic %K	47%
Beta	0.71
Analysts	Strong Sell
Price Target	$15.50